Genexplain GmbH

Genexplain GmbH is an SME in Wolfenbuttel, Germany that has taken part in 12 EU-funded projects since 2011, receiving €4.5M in EU funding.

EU funding received€4.5M
EU projects12
As coordinator0
Running now2
First EU project2011
Latest project2023
CountryGermany
EU registration (PIC)984284124
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Genexplain GmbH's own share of each project, not the project's full budget.

  • FP7 (2007 to 2013)€1.9M · 4 projects
  • Horizon Europe€1.5M · 3 projects
  • Horizon 2020€1.1M · 5 projects

Projects

12 EU-funded projects, newest first. Each links to the official record.

  • HIT-GLIOPartner

    Targeting tumour-host interactions in paediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy

    Horizon Europe · 2023–2027 · Project on CORDIS ↗

    €1.0Mtheir share
  • Chrom_rarePartner

    Unveiling the molecular basis of chromatinopathies to delineate innovative therapeutic solutions

    Horizon Europe · 2023–2027 · Project on CORDIS ↗

    €261ktheir share
  • GLIORESOLVEPartner

    Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment

    Horizon Europe · 2022–2026 · Project on CORDIS ↗

    €261ktheir share
  • PD-MitoQUANTPartner

    PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

    Horizon 2020 · 2019–2022 · Project on CORDIS ↗

    €148ktheir share
  • COLOSSUSPartner

    Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions

    Horizon 2020 · 2018–2023 · Project on CORDIS ↗

    €282ktheir share
  • GLIOTRAINPartner

    Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

    Horizon 2020 · 2017–2021 · Project on CORDIS ↗

    €249ktheir share
  • OPTOGENERAPYPartner

    Optogenetic Protein Therapy for Multiple Sclerosis

    Horizon 2020 · 2017–2020 · Project on CORDIS ↗

    €386ktheir share
  • miRNA-DisEASYPartner

    microRNA biomarkers in an innovative biophotonic sensor kit for high-specific diagnosis

    Horizon 2020 · 2015–2019 · Project on CORDIS ↗

    €18ktheir share
  • RESOLVEPartner

    A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol

    FP7 (2007 to 2013) · 2013–2018 · Project on CORDIS ↗

    €585ktheir share
  • SYSMEDIBDPartner

    Systems medicine of chronic inflammatory bowel disease

    FP7 (2007 to 2013) · 2012–2017 · Project on CORDIS ↗

    €500ktheir share
  • MIMOMICSPartner

    Methods for Integrated analysis of Multiple Omics datasets

    FP7 (2007 to 2013) · 2012–2017 · Project on CORDIS ↗

    €348ktheir share
  • SYSCOLPartner

    Systems Biology of Colorectal Cancer

    FP7 (2007 to 2013) · 2011–2015 · Project on CORDIS ↗

    €497ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • RNA
  • biochemistry
  • cardiovascular diseases
  • cells technologies
  • colorectal cancer
  • computational science
  • databases
  • diabetes
  • drug discovery
  • epidemiology
  • hepatology
  • immunotherapy
  • implants

Genexplain GmbH is listed on EUACC

See the startup profile for its product, team and what it is looking for.

Open the startup profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime